Cariprazine (Reagila®) for the treatment of schizophrenia in adult patients.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||27/11/2018|
|Rapid review completed||19/12/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cariprazine (Reagila®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
The HSE has approved reimbursement following confidential price negotiations; June 2019